Business Wire

NY-THE-BODY-SHOP

9.1.2023 07:16:30 CET | Business Wire | Press release

Share
‘No Say Day’: the Last Day Youth Voices Are Represented in Parliaments Around the World

Today is No Say Day - the last day in 2023 when young people’s voices are represented in parliaments around the world. This falls a week before world leaders and businesses gather in Davos for the World Economic Forum Annual Meeting. Often criticised for being out of touch, Davos is a prime example of the need for more youth voices in decision making spaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230108005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Antonia Tony-Fadipe, Inclusive Hiring Lead and The Body Shop Youth Collective member; Urvasi De Biasi, Activism Policy and Partnerships, The Body Shop; Lily Cannon, Activism Communications Manager, The Body Shop; Lucila San Martin, Global Activism Manager, The Body Shop (Photo: Business Wire)

Half of the world’s population is under 30, compared to just 2.6% of parliamentarians globally*. If this ratio were reflected in a year, youth voices would effectively go unheard after today. Just nine days into 2023, No Say Day is a stark demonstration of the fact that millions of young voices are excluded from decision-making spaces at a time when the world is facing extreme systemic challenges.

No Say Day is being marked as part of the Be Seen Be Heard campaign, led by The Body Shop in collaboration with the Office of the United Nations Secretary-General's Envoy on Youth to raise the voices of millions of young people in over 75 countries across six continents.

Public opinion is widely in favour of fairer political representation for young people. According to The Body Shop’s largest-ever global survey**, two thirds of people agree that the age balance in politics is wrong.

People across all age groups agree that political systems would be improved by giving young people a say in policy development. Young people are optimistic and determined to increase their involvement in public life. A third of those under age 30 surveyed would consider running for office, versus only a fifth of those over age 30.

Chris Davis, Global Sustainability and Activism Director at The Body Shop, said: “From climate change to economic instability and conflict, the world’s problems are too great to fall back on business-as-usual. Young people are energetic, thoughtful, and positive about the future – so it’s important their voices are seen and heard in parliaments around the world every day. This is clearly the preference of the public, who support a fairer approach to youth representation and trust young people’s views on the major issues of today.

“As world leaders and captains of industry gather in Davos next week, I urge them to work with young people to develop solutions to the problems we all face. Let’s make today the last No Say Day in our history.”

Jayathma Wickramanayake, the UN Secretary-General’s Envoy on Youth, said: “Young people are the experts of their own realities, and young people all over the world are making a difference every day by tackling issues that matter most to them. The idea that young people are change makers is not just a marketing campaign, it is a fact. We must dispel the myths surrounding young people, that they are irresponsible, disengaged, troublemakers, or do not have the experience to create real impact. Even in the most adverse of circumstances we have seen young people rising to the challenge and leading the way — from humanitarian crises to COVID-19 response. There is no doubt that we need young people’s innovation, drive, creativity and – more than anything – unwavering optimism that a better world is possible for everyone.”

ENDS

*https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation

**The Be Seen Be Heard Global Youth Survey

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye